Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(10 years from now) |
Tagrisso is owned by Astrazeneca.
Tagrisso contains Osimertinib Mesylate.
Tagrisso has a total of 4 drug patents out of which 0 drug patents have expired.
Tagrisso was authorised for market use on 13 November, 2015.
Tagrisso is available in tablet;oral dosage forms.
Tagrisso can be used as treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 l858r mutations in combination with pemetrexed and platinum-based chemotherapy.
Drug patent challenges can be filed against Tagrisso from 14 November, 2019.
The generics of Tagrisso are possible to be released after 02 January, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
New Indication(I-774) | Apr 18, 2021 |
New Indication(I-853) | Dec 18, 2023 |
Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 l858r mutations in combination with...
Dosage: TABLET;ORAL